

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 13th August, 2024

To, The Secretary (DCS/Compliance), Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary (Listing/Compliance), Corporate Relationship Department, National Stock Exchange of India Limited , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
--	--

Subject: Outcome of Board Meeting held on Tuesday 13th August, 2024 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Reference: Biofil Chemicals & Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors of the Company in their meeting (Serial No. 02/2024-2025) held on today i.e., Tuesday, 13th Day of August, 2024, has inter alia, considered and approved the following businesses:

1. Un-Audited Financial Results of the Company for the quarter ended on 30th June, 2024 along with limited Review Report thereon. **(Copy of financial results enclosed herewith).**
2. Approval of Board's Report on the Operation of the Company along with required annexure and Corporate Governance Report & Management Discussion and Analysis Report for the year ended March 31, 2024.
3. Convening of 39th Annual General Meeting (AGM) on Monday, 30th day of September, 2024 at 03.00 P.M. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
4. Authority to enter in to agreement for sell, transfer or otherwise dispose the whole of the undertaking of the Company situated at 11/12, Sector 'E', Sanwer Road Industrial Area, Indore – 452015 Madhya Pradesh including Leasehold land right, plant & machineries, furniture, fixtures, scraps, structure, tools, manufacturing equipments and other assets.
5. Other routine businesses with the permission of Chair.

Further, copy of aforesaid Un-Audited Financial Results of the Company shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid Un-Audited Financial Results of the Company shall also be uploaded on the Company's website i.e. www.biofilgroup.net and on the website of the Stock Exchanges i.e., at www.bseindia.com and www.nseindia.com

The extracts of the above un-audited financial results shall also be published in Hindi (Vernacular) and widely circulated English Newspaper.

Further, Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 with reference to enter in to agreement for Disposal of Undertaking.

The above information will also be available on the website of the Company at www.biofilgroup.net.

The Meeting of the Board of Directors commenced at 05.00 P.M. and concluded at 06.20 P.M.

You are requested to please take on record the same.

Thanking you.

Yours Faithfully,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

**RAMESH SHAH
CHAIRMAN AND MANAGING DIRECTOR
DIN: 00028819**

Limited Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

To,
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore (M.P.)

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("**the company**") for the quarter ended 30th June, 2024. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard (Ind As) prescribed under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and other



accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore
Date: 13th August, 2024


For Maheshwari & Gupta
Chartered Accountants
FRN: 006179C



CA Simil Maheshwari
Partner
M No. 403346
UDIN: 24403346BKALHL5983

Statement of Unaudited Financial Results for the quarter ended 30th June 2024

Sr No.	Particulars	Quarter Ended			Previous Year Ended
		June 30, 2024	June 30, 2023	March 31, 2024	March 31, 2024
		Un-Audited	Un-Audited	Audited	Audited
I	Revenue from Operation	844.34	243.35	1520.27	4003.53
II	Other Income	2.94	2.47	40.57	48.97
III	Total Income	847.28	245.82	1560.84	4052.50
IV	Expenses				
	(a) Cost of materials consumed	68.62	135.51	(1068.02)	525.743
	(b) Purchases of stock-in-trade	743.01	80.50	2436.09	3252.26
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(40.08)	(54.97)	105.30	(27.25)
	(d) Employee benefits expense	13.86	16.06	19.86	67.04
	(e) Finance Cost	1.07	1.09	2.09	4.15
	(f) Depreciation and Amortisation Expense	9.87	10.73	7.74	39.94
	(g) Other expenses	28.13	24.48	30.30	104.08
	Total expenses	824.48	213.40	1533.36	3965.97
V	Profit/ (Loss) before exceptional items and tax	22.80	32.42	27.48	86.53
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax	22.80	32.42	27.48	86.53
VIII	Tax expense:				
	(1) Current tax	5.87	8.00	11.00	24.00
	(2) Deferred tax	0.00	0.00	(8.39)	(8.39)
	Total Tax expenses	5.87	8.00	2.61	15.61
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00
X	Profit/(Loss) for the period from continuing operation	16.93	24.42	24.87	70.92
XI	Profit/(Loss) for the period for dis-continued operation	0.00	0.00	0.00	0.00
XII	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00
XIII	Profit/(Loss) for the period for dis-continued operation after tax	0.00	0.00	0.00	0.00
XIV	Profit/ (Loss) for the period	16.93	24.42	24.87	70.92
XV	Other Comprehensive Income	0.00		0.00	
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	25.67	25.67
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	(6.46)	(6.46)
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
XVI	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	16.93	24.42	44.08	90.13
XVII	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38
XVIII	Reserves (Excluding Revaluation Reserve)				(183.30)
XIX	Earnings per equity shares (for continuing operation):				
	(1) Basic (Rs)	0.10	0.15	0.15	0.44
	(2) Diluted (Rs)	0.10	0.15	0.15	0.44
XX	Earnings Per Equity Share (for discontinued operation)				
	(1) Basic (Rs)	0.00	0.00	0.00	0.00



Damegh SSheh

	(2) Diluted (Rs)	0.00	0.00	0.00	0.00
XXI	Earnings Per Equity Share (for continuing & discontinued operation)				
	(1) Basic (Rs)	0.10	0.15	0.15	0.44
	(2) Diluted (Rs)	0.10	0.15	0.15	0.44

1 The above Un-Audited Financial Results for the Quarter ended June 30, 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 13-08-2024. The above results have been reviewed by Statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

2 This financial results has been prepared in accordance with the guidelines issued by the Securities Exchange Board of India (SEBI) and Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.

4 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
a. Pharma Product
b. Chemicals Division


5 The aforesaid un-audited Financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors

6 The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter which were subjected to limited review.

Date : 13/08/2024

Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED



RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)





BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN NO. L24233MP1985PLC002709

Regd Off: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.) 452015

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

Segmentwise Revenue, Results and Capital Employed for quarter ended 30th June-2024

(Amount in Lakhs)

S.No.	Particulars	Quarter Ended			Previous Year Ended
		June 30, 2024	June 30, 2023	March 31, 2024	March 31, 2024
		Un-Audited	Un-Audited	Audited	Audited
1	Segment Revenue				
	Pharma Division	739.63	81.90	1,515.07	2,786.79
	Chemical Division	104.71	161.45	5.20	1,216.74
	Net sales/Income From Operations	844.34	243.35	1,520.27	4,003.53
2	Segment Results (Profit)(+)/ Loss (-) before tax and interest				
	Pharma Division	1.95	(17.05)	23.14	1.07
	Chemical Division	21.71	50.49	5.68	88.56
	Total Segment Profit Before Tax	23.66	33.44	28.83	89.63
	Interest Income	0.05	0.03	0.72	0.85
	Interest Expenses	0.91	1.05	2.07	3.95
	Other Unallocable Income net of Expenditure				
	Profit Before Tax	22.80	32.42	27.48	86.53
3	Capital Employed				
	Segment Assets (A)				
	Pharma Division	2,927.55	1,636.46	2,347.94	2,347.94
	Chemical Division	2,135.96	1,550.22	2,360.33	2,360.33
		5,063.51	3,186.68	4,708.27	4,708.27
	Total (A)				
	Segment Liabilities (B)				
	Pharma Division	2,306.72	1,185.84	1,976.69	1,976.69
	Chemical Division	878.17	208.40	911.30	911.30
	Total (B)	3,184.89	1,394.24	2,887.99	2,887.99
4	Total Capital Employed (Segment Assets- Segment Liabilities)				
	Pharma Division	620.83	450.62	371.25	371.25
	Chemical Division	1,257.79	1,341.83	1,449.03	1,449.03
	Total Capital Employed (Segment Assets- Segment Liabilities)	1,878.62	1,792.44	1,820.28	1,820.28

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Ramesh Shah



RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)

Date : 13/08/2024

Place : Indore